Send to:

Choose Destination
See comment in PubMed Commons below
J Dev Behav Pediatr. 2009 Oct;30(5):403-12.

Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV.

Collaborators (224)

Minglana F, Paul ME, Jackson CD, Rathore MH, Khayat A, Champion K, Cusic S, Yogev R, Chadwick E, Febo-Rodriguez I, Nieves S, Purswani M, Baksi S, Stuard E, Dummit M, Acevedo M, Gonzalez M, Fabregas L, Texidor ME, Scott GB, Mitchell CD, Taybo L, Willumsen S, Bettica L, Amour J, Dashefsky B, Dieudonne A, Van Dyke R, Silio M, Alchediak T, Borne C, Cowie M, Spector SA, Viani R, Caffery M, Proctor L, Rana S, Darbari D, Roa JC, Yu PH, Donovan M, Serrano R, Burey M, Auguste R, Chen J, Foster J, Stechenberg BW, Fisher DJ, Johnston AM, Toye M, Homans J, Neely M, Spencer LS, Kovacs A, Burchett S, Karthas N, Moore E, Cromer C, Flynn PM, Patel N, Donohoe M, Jones S, Borkowsky W, Chandwani S, Deygoo N, Akleh S, Handelsman E, Moallem HJ, Swindell DM, Kaye JM, Higgins A, Foca M, LaRussa P, Gershon A, Rutstein RM, Vincent CA, Douglas SD, Koutsoubis GA, Petru A, Courville T, Wara D, Trevithick D, McFarland E, Salbenblatt C, Hutton N, Griffith B, Joyner M, Kiefner C, Acker M, Croteau R, McLellan C, Mohan K, Bamji M, Pathak I, Manwani S, Patel E, Spiegel H, Amos V, Luzuriaga K, Pass R, Crain M, Farley J, Klipner K, Bonagura VR, Schuval SJ, Colter C, Campbell L, Pelton SI, Reagan AM, Rich KC, Hayani K, Bicchinella M, Nachman S, Ferraro D, Madjar S, Puga A, Wiley F, Whitfield K, Johnson O, Dizney R, Champion S, Frere M, DiGrado M, Abrams EJ, Martinez J, Mancao M, Salazar J, Karas G, Belho T, Pitkin B, Eddleman J, Figueroa W, Reyes E, Weiner LB, Contello KA, Holz WA, Famiglietti MJ, Lawrence R, Lew J, Delany C, Duff C, Fernandez AD, Hughes PA, Wade N, Adams ME, Piatt JP, Foti J, Clarke-Steffen L, Sleasman J, Delaney C, Mani CS, Andiman WA, Romano S, Hurst L, de Jesus J, Wilson G, Weinberg GA, Gigliotti F, Murante B, Laverty S, Hutchcon N, Townley A, Nesheim S, Dennis R, Emmanuel P, Lujan-Zilberman J, Graisberry C, Moore S, Fisher RG, Cunnion KM, Rubio TT, Sandifer D, Johnson GM, Gay H, Sadler S, Keller M, Hayes J, Gagajena A, Mink C, Johnson D, Church J, Dunaway T, Salata C, Deveikis A, Melton L, Gaur S, Whitley-Williams P, Malhotra A, Cerracchio L, Dolan M, D'Agostino J, Posada R, Mani C, Cobb S, Lavoie SR, Smith TY, Feingold A, Burrows-Clark S, Mrus J, Beiting R, Brady M, Hunkler J, Koranyi K, Albritton W, Warford R, Arpadi S, Gershon A, Miller P, Rubinstein A, Krienik G, Kovacs A, Operskalski E, Wara D, Kamrin A, Farrales S, Johan-Liang R, O'Keefe K, McGann KA, Pickering L, Storch GA, Pahwa S, Rodriquez L, Lewis P, Croteau R.



To examine the relationships between physical growth and medications prescribed for symptoms of attention-deficit hyperactivity disorder in children with HIV.


Analysis of data from children with perinatally acquired HIV (N = 2251; age 3-19 years), with and without prescriptions for stimulant and nonstimulant medications used to treat attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight measurements were transformed to z scores and compared across medication groups. Changes in z scores during a 2-year interval were compared using multiple linear regression models adjusting for selected covariates.


Participants with (n = 215) and without (n = 2036) prescriptions were shorter than expected based on US age and gender norms (p < .001). Children without prescriptions weighed less at baseline than children in the general population (p < .001) but gained height and weight at a faster rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight; their height and weight growth velocities were comparable with the general population and children without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants had the lowest baseline height but were similar to population norms in baseline weight. Their height and weight growth velocities were comparable with the general population but significantly slower than children without prescriptions (p = .01 and .02, respectively).


The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder does not significantly exacerbate the potential for growth delay in children with HIV and may afford opportunities for interventions that promote physical growth. Prospective studies are needed to confirm these findings.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk